4D Molecular Therapeutics Inc at Jefferies Healthcare Conference Transcript
I'm a member of the biotechnology research team at Jefferies, and it is my great pleasure to introduce Dr. David Kirn, CEO of 4D Molecular Therapeutics, and Julian Pei, Director in Corporate Finance at 4D Molecular Therapeutics.
Thanks for having us, and David, unfortunately, couldn't make it today, but he's on Zoom right now. So thank you, everyone, for coming today. Today we'll have a quick presentation, then some Q&A.
So first, going over 4D's pipeline. So we have a very deep pipeline in three therapeutic areas, ophthalmology, pulmonology, and cardiology, all using vectors invented and customized at 4DMT for lower doses, lower immunogenicity. These are next-generation vectors, and specifically, our lead programs in ophthalmology are 4D-150 in wet AMD, which expresses a flipper septum at VEGF-C RNAi, and geographic atrophy as well for 4D-175. All of these are large, sustainable, high-incidence markets, and we own rights to all
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |